secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0000950170-23-047822
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology expects to file IND for SC291 in autoimmune diseases in Q4 2023, with clinical data in 2024
--------------------------------------------------------------------------------

- Sana expects to file investigational new drug application for SC291 in autoimmune diseases in Q4 2023.
- Clinical data from SC291 in autoimmune diseases expected in 2024.
- Announcement made at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017023047822/0000950170-23-047822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017023047822/sana-20230912.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-047822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer